340B Program Update: Rebate Model, Contract Pharmacies, Duplicate Discounts, & What Manufacturers Need to Know
340B Program Update: What Manufacturers Need to Know Right Now
The 340B program is moving faster than at any point in its history. Rebate model pilot programs, contract pharmacy state legislation, the rise of all 340B claim collection, and a duplicate discount problem now estimated at over $20 billion annually…manufacturers are navigating a landscape where standing still is no longer an option.
In this white paper, Advisory Services Partner Clay Willis breaks down the four most critical developments reshaping 340B strategy today, drawing from his recent webinar and his presentation at the Informa Pricing and Contracting USA conference. You'll come away with a clear-eyed view of what's working, what isn't, and where the program is likely headed over the next 12 to 24 months.
About the Author
Clay is a Partner of Advisory Services at IntegriChain, with over 18 years of consulting experience in the pharmaceutical industry. This includes providing operational, financial, compliance, and strategy-related support to small, mid-size, and large pharmaceutical manufacturers. Clay has experience assisting pharmaceutical manufacturers’ understanding of the 340B program and creating strategies to address this ever-changing program.
His work includes evaluating growth drivers of the program and why they are occurring, then assessing and/or implementing channel mitigation strategies. Some strategy examples: contract pharmacy policies, mitigation of stakeholder workarounds, payer (commercial, Medicaid, and Medicare) duplicate discount scrubbing, and evaluating patient definition and alternative chargeback models (rebate model). Clay has created and implemented a 340B Center of Excellence within pharmaceutical manufacturers, which established an overall governance and operating model as well as hired dedicated 340B resources to support the evolving and complex program.